Daniel J Zheng1, Kyaw Sint2, Hannah-Rose Mitchell3, Nina S Kadan-Lottick3,4. 1. Yale University School of Medicine Section of Pediatric Hematology and Oncology, 333 Cedar Street, LMP 2073, New Haven, CT, 06510, USA. daniel.zheng@yale.edu. 2. Yale University School of Public Health Department of Biostatistics, New Haven, CT, USA. 3. Yale University School of Medicine Section of Pediatric Hematology and Oncology, 333 Cedar Street, LMP 2073, New Haven, CT, 06510, USA. 4. Yale Cancer Center, New Haven, CT, USA.
Abstract
PURPOSE: Because many survivors do not receive recommended follow-up, we sought to characterize patterns and predictors of survivorship clinic attendance in a population-based sample of childhood cancer survivors. METHODS: Using the Connecticut Tumor Registry, we identified all patients diagnosed with cancer at age ≤ 18 years from March 1, 1998 to March 1, 2008, still in follow-up 5 years post-diagnosis, and living <100 miles from Yale. Survivorship clinic attendance, demographics, disease characteristics, and treatment exposures were ascertained. Vital status was confirmed with the National Death Index. The Kaplan-Meier curves and hazard ratios were calculated for survivorship clinic attendance. RESULTS: Four hundred eighty-nine eligible survivors currently 19.1 ± 6.2 years old were diagnosed at a mean age of 9.1 ± 5.8 years with leukemias/lymphomas (47.2 %), central nervous system tumors (16.4 %), sarcomas (11.2 %), thyroid cancers or melanomas (7.8 %), and other solid tumors (17.4 %). The 10-year post-diagnosis clinic attendance probability was 27.8 % (SE = 2.3) overall, and 36.9 % (SE = 4.4) and 40.8 % (SE = 3.8), in patients with radiation and anthracycline exposure, respectively. In adjusted analysis, patients with insurance (HR = 2.90; p < 0.01 for private and HR = 2.05; p = 0.02 for public assistance), treated with anthracyclines (HR = 3.05; p < 0.01), and treated with radiation (HR = 1.90; p < 0.01) were significantly more likely to attend clinic. CONCLUSIONS: The majority of childhood cancer survivors in our population-based sample had not attended survivorship clinic, even among those with high-risk exposures. Health care access, as measured by insurance status, was an important predictor of clinic attendance. IMPLICATIONS FOR CANCER SURVIVORS: More research is needed to clarify the link between insurance status and survivorship care to increase appropriate late effects surveillance in this population.
PURPOSE: Because many survivors do not receive recommended follow-up, we sought to characterize patterns and predictors of survivorship clinic attendance in a population-based sample of childhood cancer survivors. METHODS: Using the Connecticut Tumor Registry, we identified all patients diagnosed with cancer at age ≤ 18 years from March 1, 1998 to March 1, 2008, still in follow-up 5 years post-diagnosis, and living <100 miles from Yale. Survivorship clinic attendance, demographics, disease characteristics, and treatment exposures were ascertained. Vital status was confirmed with the National Death Index. The Kaplan-Meier curves and hazard ratios were calculated for survivorship clinic attendance. RESULTS: Four hundred eighty-nine eligible survivors currently 19.1 ± 6.2 years old were diagnosed at a mean age of 9.1 ± 5.8 years with leukemias/lymphomas (47.2 %), central nervous system tumors (16.4 %), sarcomas (11.2 %), thyroid cancers or melanomas (7.8 %), and other solid tumors (17.4 %). The 10-year post-diagnosis clinic attendance probability was 27.8 % (SE = 2.3) overall, and 36.9 % (SE = 4.4) and 40.8 % (SE = 3.8), in patients with radiation and anthracycline exposure, respectively. In adjusted analysis, patients with insurance (HR = 2.90; p < 0.01 for private and HR = 2.05; p = 0.02 for public assistance), treated with anthracyclines (HR = 3.05; p < 0.01), and treated with radiation (HR = 1.90; p < 0.01) were significantly more likely to attend clinic. CONCLUSIONS: The majority of childhood cancer survivors in our population-based sample had not attended survivorship clinic, even among those with high-risk exposures. Health care access, as measured by insurance status, was an important predictor of clinic attendance. IMPLICATIONS FOR CANCER SURVIVORS: More research is needed to clarify the link between insurance status and survivorship care to increase appropriate late effects surveillance in this population.
Entities:
Keywords:
Childhood cancer survivorship; Health services; Healthcare access; Long-term follow-up care; Surveillance
Authors: Gisela Michel; Claudia E Kuehni; Cornelia E Rebholz; Karin Zimmermann; Christine Eiser; Corina S Rueegg; Nicolas X von der Weid Journal: Psychooncology Date: 2010-08-04 Impact factor: 3.894
Authors: Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo Journal: Nat Rev Clin Oncol Date: 2011-06-28 Impact factor: 66.675
Authors: Benjamin D Sommers; Thomas Buchmueller; Sandra L Decker; Colleen Carey; Richard Kronick Journal: Health Aff (Millwood) Date: 2012-12-19 Impact factor: 6.301
Authors: Elyse R Park; Frederick P Li; Yan Liu; Karen M Emmons; Arthur Ablin; Leslie L Robison; Ann C Mertens Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 50.717
Authors: Paul C Nathan; Mark L Greenberg; Kirsten K Ness; Melissa M Hudson; Ann C Mertens; Martin C Mahoney; James G Gurney; Sarah S Donaldson; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2008-09-20 Impact factor: 50.717
Authors: Judy Y Ou; Rochelle R Smits-Seemann; Yelena P Wu; Jennifer Wright; Anne C Kirchhoff Journal: J Cancer Surviv Date: 2017-11-29 Impact factor: 4.442
Authors: Katie A Devine; Adrienne Viola; Peter Capucilli; Olle Jane Z Sahler; Jeffrey R Andolina Journal: J Pediatr Hematol Oncol Date: 2017-04 Impact factor: 1.289
Authors: Amy M Berkman; Abenaa M Brewster; Lee W Jones; Jun Yu; J Jack Lee; S Andrew Peng; Abigail Crocker; Joann L Ater; Susan C Gilchrist Journal: J Adolesc Young Adult Oncol Date: 2017-05-22 Impact factor: 2.223
Authors: Paul C Nathan; Mohammad Agha; Jason D Pole; David Hodgson; Astrid Guttmann; Rinku Sutradhar; Mark L Greenberg Journal: J Cancer Surviv Date: 2016-02-11 Impact factor: 4.442
Authors: Kelley K Hutchins; Süreyya Savaşan; Ronald L Thomas; Laura A Strathdee; Zhihong J Wang; Jeffrey W Taub Journal: J Pediatr Hematol Oncol Date: 2019-01 Impact factor: 1.289
Authors: K Reynolds; M Spavor; Y Brandelli; C Kwok; Y Li; M Disciglio; L E Carlson; F Schulte; R Anderson; P Grundy; J Giese-Davis Journal: J Cancer Surviv Date: 2019-06-27 Impact factor: 4.442
Authors: Lindsay Hedden; Phil Pollock; Bryan Stirling; Larry Goldenberg; Celestia Higano Journal: Support Care Cancer Date: 2019-06-25 Impact factor: 3.603
Authors: Dava Szalda; Lisa Piece; Lauren Brumley; Yimei Li; Marilyn M Schapira; Monika Wasik; Wendy L Hobbie; Jill P Ginsberg; Lisa A Schwartz Journal: J Adolesc Health Date: 2016-10-27 Impact factor: 5.012
Authors: Miranda M Fidler-Benaoudia; Kevin C Oeffinger; Yutaka Yasui; Leslie L Robison; David L Winter; Raoul C Reulen; Wendy M Leisenring; Yan Chen; Gregory T Armstrong; Michael M Hawkins Journal: J Natl Cancer Inst Date: 2021-05-04 Impact factor: 13.506